Li Xinna, Han Peihai, Liu Mengjiao, Li Xiaowen, Xue Shuai
The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Department of Pathology, Yantai, China.
Traditional Chinese Medical Hospital of Huangdao District, Encephalopathy Department, Qingdao, China.
J Med Biochem. 2023 Aug 25;42(3):505-512. doi: 10.5937/jomb0-42550.
This study was aimed to evaluate the efficacy of pramipexole combined with ganglioside for PD treatment and pramipexole monotherapy, so as to provide reference for clinical practice.
61 PD patients selected from June 2019 to December 2020 at our hospital were divided into two groups. The control group (n=31) was given dopasizide oral treatment, and the treatment group (n=30) was given ganglioside combined with pramipexole. The clinical efficacy, adverse reactions, motor function scores, UPDRS scores, PDQ-39 scale scores, TNF-a levels, and related serum factor levels were measured in this study.
本研究旨在评估普拉克索联合神经节苷脂治疗帕金森病（PD）的疗效以及普拉克索单药治疗的效果，为临床实践提供参考。
选取2019年6月至2020年12月在我院就诊的61例PD患者，分为两组。对照组（n = 31）给予多巴丝肼口服治疗，治疗组（n = 30）给予神经节苷脂联合普拉克索治疗。本研究测定了临床疗效、不良反应、运动功能评分、统一帕金森病评定量表（UPDRS）评分、帕金森病生活质量问卷（PDQ - 39）量表评分、肿瘤坏死因子-α（TNF - a）水平及相关血清因子水平。
